Skip to Content

Cipro XR Side Effects

Generic Name: ciprofloxacin

Note: This page contains information about the side effects of ciprofloxacin. Some of the dosage forms included on this document may not apply to the brand name Cipro XR.

Not all side effects for Cipro XR may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to ciprofloxacin: oral powder for suspension, oral tablet

Other dosage forms:

In addition to its needed effects, some unwanted effects may be caused by ciprofloxacin (the active ingredient contained in Cipro XR). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking ciprofloxacin:

More common
  • Diarrhea
  • Bloody or black, tarry stools
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • changes in skin color
  • changes in urination
  • chest pain or discomfort
  • chest tightness or heaviness
  • chills or fever
  • clumsiness or unsteadiness
  • confusion
  • continuing ringing or buzzing or other unexplained noise in the ears
  • coughing or spitting up blood
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast, irregular, pounding, or racing heartbeat or pulse
  • headache, severe and throbbing
  • hearing loss
  • hives or welts
  • joint stiffness
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • light-colored stools
  • muscle pain or stiffness
  • nausea and vomiting
  • nightmares
  • numbness of the hands
  • pain in the joints
  • pain or discomfort in the arms, jaw, back, or neck
  • painful, red lumps under the skin, mostly on the legs
  • pounding in the ears
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • redness of the face, neck, arms, and occasionally, upper chest
  • seizures
  • severe abdominal or stomach pain, cramping, or burning
  • shakiness in the legs, arms, hands, or feet
  • skin rash
  • swelling of the face, feet, or lower legs
  • swollen, painful, or tender lymph glands in the neck, armpit, or groin
  • thick, white vaginal discharge with no odor or with a mild odor
  • unsteadiness, trembling, or other problems with muscle control or coordination
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • white patches in the mouth and/or on the tongue
  • yellow eyes or skin
Incidence not known
  • Acid or sour stomach
  • blistering, peeling, or loosening of the skin
  • bluish-colored lips, fingernails, or palms
  • bone pain
  • diarrhea, watery and severe, which may also be bloody
  • difficulty with breathing, chewing, or talking
  • double vision
  • excessive muscle tone
  • feeling of discomfort
  • feeling, seeing, or hearing things that are not there
  • increased sensitivity to pain
  • increased sensitivity to touch
  • irregular or slow heart rate
  • mood changes
  • nosebleeds
  • rapid heart rate
  • red skin lesions, often with a purple center
  • sores, ulcers, or white spots on the lips or in the mouth
  • unusual bleeding or bruising
  • unusual excitement, nervousness, or restlessness
  • vaginal yeast infection

Some of the side effects that can occur with ciprofloxacin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Runny nose
  • sneezing
  • stuffy nose

For Healthcare Professionals

Applies to ciprofloxacin: intravenous solution, oral powder for reconstitution, oral tablet, oral tablet extended release


In clinical trials with oral and parenteral ciprofloxacin (the active ingredient contained in Cipro XR) 49,038 patients received courses of the drug. Most side effects were described as mild to moderate, subsided soon after the drug was discontinued, and required no treatment. Oral and IV ciprofloxacin were discontinued due to side effects in 1% and 1.8% of patients, respectively. IV ciprofloxacin was most frequently (greater than 1%) associated with nausea, diarrhea, central nervous system disturbance, local IV site reactions, abnormal liver function tests, eosinophilia, headache, restlessness, and rash; the majority of which were of mild to moderate severity. The most frequently reported drug-related effects, from clinical trials of all formulations, all dosages, all drug-therapy durations, and for all indications of ciprofloxacin therapy were nausea, diarrhea, abnormal liver function tests, vomiting, and rash.

Among patients surveyed by the CDC, more than 1000 received only ciprofloxacin for inhalational anthrax postexposure prophylaxis. Gastrointestinal side effects (nausea, vomiting, diarrhea, or stomach pain); neurological side effects (problems sleeping, nightmares, headache, dizziness, lightheadedness), and musculoskeletal side effects (muscle or tendon pain and joint swelling or pain) occurred more often than in previous controlled trials. This higher incidence, without a control group, may be due to reporting bias, concurrent medical conditions, other concomitant medications, emotional stress or other confounding factors, and/or a longer duration of ciprofloxacin therapy. Due to such factors, it was difficult to determine if the reported side effects were drug-related.[Ref]


Common (1% to 10%): Nausea (up to 4%), diarrhea (up to 2%), vomiting (up to 2%)
Uncommon (0.1% to 1%): Abdominal pain/discomfort, Clostridium difficile-associated diarrhea, constipation, dyspepsia, epigastric pain, dysphagia, flatulence, gastrointestinal bleeding, ileus, intestinal perforation, elevated amylase, elevated lipase, mouth dryness, oral candidiasis, oral ulceration, painful oral mucosa, pancreatitis, pseudomembranous colitis
Rare (less than 0.1%): Elevated serum amylase
Frequency not reported: Heartburn, acid reflux, aggravated irritable bowel syndrome, lower abdominal pain
Postmarketing reports: Clostridium difficile-associated diarrhea, constipation, dyspepsia, dysphagia, flatulence, gastrointestinal bleeding, ileus, intestinal perforation, elevated amylase, elevated lipase, oral and gastrointestinal moniliasis, oral candidiasis, oral ulceration, pancreatitis, pseudomembranous colitis[Ref]

The onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.

Extended-release ciprofloxacin (Proquin XR) reportedly has been associated with a lower incidence of gastrointestinal side effects.[Ref]


Common (1% to 10%): Rash (IV: greater than 1%)
Uncommon (0.1% to 1%): Rash, pruritus, urticaria, cutaneous candidiasis, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis (Lyell's syndrome), increased perspiration, burning, erythema, erythema nodosum, photosensitivity/phototoxicity reaction, dry skin, maculopapular rash, skin disorder, vesiculobullous rash, hyperpigmentation, sweating
Rare (less than 0.1%): Photoinduced acute exanthematous pustulosis (at least 1 case)
Frequency not reported: Bullous pemphigoid
Postmarketing reports: Cutaneous candidiasis, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis (Lyell's syndrome), increased perspiration, erythema nodosum, photosensitivity/phototoxicity reaction, hyperpigmentation, sweating, acute generalized exanthematous pustulosis (AGEP)[Ref]

Photosensitivity is seen most frequently when patients are exposed to intense sun, as for example when used for the treatment or prophylaxis of traveler's diarrhea.

A 27-year-old woman with mild systemic erythematosus developed toxic epidermal necrolysis (TEN) after starting a second course of oral ciprofloxacin following a previous 5-day course. She developed a rash, high fever, and diarrhea after taking the second dose and presented with diffuse rash, epidermal sloughing of 60% of the skin, desquamation of the lips, shock, and respiratory distress. She died on the twenty-eighth hospital day of TEN, right ventricular failure, and acute respiratory distress syndrome. As of 2003, 9 cases of TEN, including 5 fatalities, have been reported in the literature.[Ref]

Nervous system

One survey reported 11 cases of peripheral neuropathy associated with ciprofloxacin (the active ingredient contained in Cipro XR) The severity ranged from mild and reversible to severe and persistent. In one case, a 44-year-old female developed numbness, allodynia, hypoesthesia, tremors, electrical and diffuse burning sensations, twitching, disorientation, visual impairment, nausea, temperature intolerance, rash, and palpitations, and remained disabled after 29 months.

Seizures have been reported in 2 patients given ciprofloxacin and foscarnet. The temporal association between the onset of seizures and drug administration suggests a possible drug interaction, although a causal relationship could not be established in either case. Ciprofloxacin and foscarnet are individually epileptogenic, and their concurrent use may potentiate the risk of seizures.[Ref]

Common (1% to 10%): Headache (up to 3%; IV: greater than 1%), dizziness (up to 2%), restlessness (IV: greater than 1%), central nervous system disturbance (IV: greater than 1%)
Uncommon (0.1% to 1%): Abnormal gait, ataxia, convulsive seizures (including status epilepticus), grand mal convulsion, irritability, lightheadedness, paresthesia, restlessness, syncope, tremor, weakness, unresponsiveness, tinnitus, hearing loss, bad taste, anosmia, migraine, incoordination, vertigo, taste perversion
Frequency not reported: Disturbance in attention, benign intracranial hypertension, dysesthesia, dyskinesia, neuropathy, paresis, aseptic meningitis
Postmarketing reports: Abnormal gait, ataxia, grand mal convulsion, lightheadedness, paresthesia, restlessness, unresponsiveness, agitation, hyperesthesia, hypoesthesia, tinnitus, hearing loss, taste loss, anosmia, migraine, peripheral neuropathy (may be irreversible), polyneuropathy, twitching, convulsion[Ref]


At least two cases have been reported of patients developing a cutaneous vasculitis related to ciprofloxacin (the active ingredient contained in Cipro XR) use. The vasculitis resolved without medical intervention following discontinuation of the drug.

Anaphylactic reactions may occur at an increased incidence among HIV-infected individuals.[Ref]

Uncommon (0.1% to 1%): Allergic reactions, anaphylactic reactions (including life-threatening anaphylactic shock), vasculitis, angioedema, edema (lips, face, neck, conjunctivae, hands, or lower extremities), vesicles
Frequency not reported: Allergic interstitial nephritis, lobular panniculitis, anaphylactoid reactions, necrotizing vasculitis, cutaneous vasculitis
Postmarketing reports: Allergic reactions (ranging from urticaria to anaphylactic reactions, including life-threatening anaphylactic shock), fixed eruptions, vasculitis, angioedema, edema (lips, face, neck, conjunctivae, hands, or lower extremities), vesicles, serum sickness-like reaction[Ref]


The most frequently reported changes in laboratory parameters with IV ciprofloxacin (the active ingredient contained in Cipro XR) included elevated ALT, AST, alkaline phosphatase, LDH, and serum bilirubin.[Ref]

Common (1% to 10%): Elevated ALT (1.9%), elevated AST (1.7%), abnormal liver function tests (up to 1.3%)
Uncommon (0.1% to 1%): Elevated alkaline phosphatase (0.8%), elevated LDH (0.4%), elevated serum bilirubin (0.3%), cholestatic jaundice, hepatitis, hepatic necrosis, jaundice
Rare (less than 0.1%): Elevated serum gamma glutamyltransferase
Postmarketing reports: Cholestatic jaundice, hepatitis, hepatic necrosis, hepatic failure (including fatal cases), jaundice[Ref]


The most frequently reported changes in laboratory parameters with IV ciprofloxacin (the active ingredient contained in Cipro XR) included elevated serum creatinine, BUN, and uric acid.

Allergic interstitial nephritis resulting in nonoliguric renal failure has been described in a number of case reports. Several of the cases have included symptoms of rash, fever, and arthralgia and have been accompanied by eosinophilia and eosinophiluria. The cases of allergic interstitial nephritis have often responded to short courses of corticosteroid therapy.[Ref]

Common (1% to 10%): Elevated serum creatinine (1.1%)
Uncommon (0.1% to 1%): Elevated BUN (0.9%), renal failure, interstitial nephritis, nephritis, renal calculi, abnormal kidney function
Rare (less than 0.1%): Elevated uric acid, decreased BUN, decreased uric acid
Frequency not reported: Myoglobin-associated acute kidney injury/failure
Postmarketing reports: Renal failure, interstitial nephritis, nephritis, renal calculi[Ref]


Local IV site reactions occurred more often if the infusion time was 30 minutes or less.

Injection site irritation and induration have been reported with IV infusion over less than 30 minutes or when a small vein in the back of the hand was used. The manufacturer recommends an infusion time of 1 hour.[Ref]

Common (1% to 10%): Local IV site reactions (IV: greater than 1%)
Uncommon (0.1% to 1%): Injection site reaction
Frequency not reported: Injection site irritation and induration with IV infusion[Ref]


The most frequently reported changes in laboratory parameters with IV ciprofloxacin (the active ingredient contained in Cipro XR) included elevated serum creatine phosphokinase.

Arthropathy is primarily a concern in pediatric patients. However, at least one case was described in an adult cystic fibrosis patient receiving ciprofloxacin. Although cystic fibrosis arthropathy (CFA) and hypertrophic pulmonary osteoarthropathy (HPOA) typically occur in 7% to 8% of the cystic fibrosis adult and adolescent population, the arthropathy exhibited in this patient did not resemble either. Several elements in its presentation strongly support the diagnosis of ciprofloxacin-induced arthropathy, such as: a consistent time of onset with other reported cases of suspected quinolone-induced arthropathy (usually 3 weeks after initiating therapy); a lack of history of arthralgia in the patient; reoccurrence upon rechallenge; and resolution of symptoms upon discontinuation of therapy (usually 2 weeks after termination of therapy).

Tendinitis with subsequent tendon rupture has been documented in a number of case reports. One patient with chronic renal failure developed bilateral Achilles tendon rupture after four days of ciprofloxacin therapy. Although renal transplant patients and those with end-stage renal disease tend to have an increased risk of Achilles tendinitis and rupture over the general population, quinolone use has been shown to further increase that risk (12% in quinolone-treated patients vs. 7% in nonquinolone-treated patients).

Twenty-five cases of Achilles tendon rupture have been reported to the FDA as of October 1994. Some ruptures have also occurred in the hand or shoulder. Other risk factors identified include age and corticosteroid use.[Ref]

Uncommon (0.1% to 1%): Jaw, arm, or back pain, neck and/or chest pain, arthralgia, back pain, joint stiffness, achiness, myasthenia gravis, muscle weakness, gout flare-up, hypertonia
Frequency not reported: Joint swelling, muscle spasms, night cramps, elevated serum creatine phosphokinase, knee inflammation, suspected cases of reversible arthropathy
Postmarketing reports: Arthralgia, joint stiffness, achiness, gout flare-up, hypertonia, myoclonus, myasthenia, exacerbation of myasthenia gravis, tendinitis, tendon rupture, myalgia[Ref]


Uncommon (0.1% to 1%): Angina pectoris, arrhythmia, atrial flutter, cardiac murmur, cardiopulmonary arrest, cardiovascular collapse, cerebral thrombosis, hypertension, hypotension, myocardial infarction, palpitation, phlebitis/thrombophlebitis, tachycardia, vasodilation, ventricular ectopy, bradycardia
Frequency not reported: Ventricular bigeminy, abdominal aortic bruit
Postmarketing reports: Angina pectoris, arrhythmia, atrial flutter, cardiac murmur, cardiopulmonary arrest, cardiovascular collapse, cerebral thrombosis, hypertension, hypotension, myocardial infarction, palpitation, phlebitis, tachycardia, ventricular ectopy, QT prolongation, torsade de pointes, ventricular arrhythmia, postural hypotension[Ref]


Common (1% to 10%): Eosinophilia (IV: greater than 1%)
Uncommon (0.1% to 1%): Lymphadenopathy, petechiae, eosinophilia (0.6%), leukopenia (0.4%), decreased blood platelets (0.1%), increased blood platelets (0.1%), pancytopenia (up to 0.1%), agranulocytosis, prolongation of prothrombin time, purpura, decreased prothrombin time
Rare (less than 0.1%): Anemia, bleeding diathesis, decreased hemoglobin, decreased leukocytes, increased atypical lymphocyte count, immature white blood cells, increased blood monocytes, leukocytosis, hemolytic anemia, elevated sedimentation rate
Frequency not reported: Decreased hematocrit, thrombocytopenia, neutropenia
Postmarketing reports: Lymphadenopathy, petechiae, pancytopenia, agranulocytosis, anemia, bleeding diathesis, marrow depression (including life-threatening), prolongation of prothrombin time, hemolytic anemia, purpura, decreased prothrombin time, life-threatening or fatal pancytopenia, methemoglobinemia, increased international normalized ratio (INR) (in patients treated with vitamin K antagonists)[Ref]

The most frequently reported changes in laboratory parameters with IV ciprofloxacin included elevated eosinophil and platelet counts, decreased platelet counts, hemoglobin and/or hematocrit.[Ref]


Uncommon (0.1% to 1%): Anorexia, hyperglycemia, hypoglycemia, acidosis
Rare (less than 0.1%): Elevated serum calcium, elevated serum cholesterol, elevated serum potassium, decreased serum albumin, decreased serum potassium, decreased total serum protein, decreased blood glucose
Frequency not reported: Symptomatic hypoglycemia
Postmarketing reports: Acidosis, elevated serum triglycerides, elevated serum cholesterol, elevated blood glucose, elevated serum potassium[Ref]

The most frequently reported changes in laboratory parameters with IV ciprofloxacin included elevated blood glucose and triglycerides.

Quinolone class antibiotics have been associated with symptomatic hypoglycemia.[Ref]


Uncommon (0.1% to 1%): Anxiety, confusion, drowsiness, depersonalization, depression (potentially culminating in self-injurious behavior, such as suicidal ideations/thoughts and attempted or completed suicide), dysphasia, hallucinations, insomnia, lethargy, manic reaction, nightmares, paranoia, phobia, toxic psychosis, abnormal dreams, somnolence
Frequency not reported: Catatonia
Postmarketing reports: Anxiety, confusion, delirium, drowsiness, hallucinations, lethargy, manic reaction, nightmares, paranoia, phobia, toxic psychosis[Ref]


Uncommon (0.1% to 1%): Bronchospasm, dyspnea, epistaxis, hemoptysis, hiccough, laryngeal or pulmonary edema, pleural effusion, pulmonary embolism, respiratory arrest, respiratory distress
Frequency not reported: Wheeze, cough, upper respiratory tract infection, pharyngitis, nasopharyngitis
Postmarketing reports: Bronchospasm, dyspnea, epistaxis, hemoptysis, hiccough, laryngeal or pulmonary edema, pleural effusion, pulmonary embolism, respiratory arrest, respiratory distress[Ref]


Uncommon (0.1% to 1%): Decreased visual acuity, blurred vision, visual disturbances (flashing lights, overbrightness of lights, change in color perception), chromatopsia, diplopia, nystagmus, eye pain
Frequency not reported: Cataracts, multiple punctate lenticular opacities
Postmarketing reports: Decreased visual acuity, blurred vision, visual disturbances (flashing lights, overbrightness of lights, change in color perception), chromatopsia, nystagmus[Ref]

Quinolone class antibiotics have been associated with cataracts and multiple punctate lenticular opacities.[Ref]


Crystalluria has been reported in patients with alkaline urine and does not necessarily lead to nephrotoxicity. At physiological urinary pH, the risk of crystalluria is considered minor.[Ref]

Common (1% to 10%): Vaginal moniliasis (up to 2%)
Uncommon (0.1% to 1%): Albuminuria, breast pain, candiduria, cylindruria, crystalluria, frequent urination, gynecomastia, hematuria, hemorrhagic cystitis, polyuria, urethral bleeding, urinary retention, vaginitis, dysmenorrhea
Frequency not reported: Urinary tract infection, fungal vaginosis, bacterial vaginitis, dysuria, abnormal urine odor, female genital pruritus, vaginal infection, urinary frequency, micturition urgency
Postmarketing reports: Albuminuria, candiduria, frequent urination, gynecomastia, hemorrhagic cystitis, polyuria, urethral bleeding, urinary retention, vaginal candidiasis, vaginal pruritus, vaginal moniliasis[Ref]


Uncommon (0.1% to 1%): Pain, foot pain, extremity pain, fever, chills, flushing, swelling, malaise, asthenia, thirst
Rare (less than 0.1%): Serum phenytoin alteration, Jarisch-Herxheimer reaction (at least 1 case)
Frequency not reported: Fatigue, suprapubic pain, rigors, tenderness, fungal infection, increased body temperature, elevated serum theophylline
Postmarketing reports: Fever, chills, flushing, serum phenytoin alteration, pain (arm, back, breast, chest, epigastric, eye, extremities, foot, jaw, neck, oral mucosa)[Ref]

The most frequently reported changes in laboratory parameters with IV ciprofloxacin included elevated serum theophylline (in patients receiving theophylline concomitantly).

Oral ciprofloxacin has been associated with a case of Jarisch-Herxheimer reaction, characterized by hypotension, tachycardia, and disseminated intravascular coagulation, in a 14-year-old female with tickborne relapsing fever.[Ref]


1. Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A "Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 35 (1988): 373-447

2. Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991): 378-83

3. "From the Centers for Disease Control and Prevention. Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001." JAMA 286 (2001): 2935-6

4. Drossou-Agakidou V, Roilides E, Papakyriakidou-Koliouska P, et al. "Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year." Pediatr Infect Dis J 23 (2004): 346-349

5. Fourcroy JL, Berner B, Chiang YK, Cramer M, Rowe L, Shore N "Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women." Antimicrob Agents Chemother 49 (2005): 4137-43

6. "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.

7. Kothur K, Singh M, Dayal D "Ciprofloxacin-induced anaphylactoid reaction." Eur J Pediatr 165 (2006): 573-4

8. Heyd A, Haverstock D "Retrospective analysis of the safety profile of oral and intravenous ciprofloxacin in a geriatric population." Clin Ther 22 (2000): 1239-50

9. Ramakrishnan K, Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42

10. Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93

11. Juillerat P, Pittet V, Felley C, et al. "Drug safety in Crohn's disease therapy." Digestion 76 (2007): 161-8

12. Alexander RB, Propert KJ, Schaeffer AJ, et al. "Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial." Ann Intern Med 141 (2004): 581-9

13. Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989): s98-102

14. Overholser BR, Kays MB, Forrest A, Sowinski KM "Sex-related differences in the pharmacokinetics of oral ciprofloxacin." J Clin Pharmacol 44 (2004): 1012-22

15. Harmon T, Burkhart G, Applebaum H "Perforated pseudomembranous colitis in the breast-fed infant." J Pediatr Surg 27 (1992): 744-6

16. Bauwens JE, McFarland LV, Melcher SA "Recurrent clostridium difficile disease following ciprofloxacin use." Ann Pharmacother 31 (1997): 1090

17. Bilton D, Henig N, Morrissey B, Gotfried M "Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis." Chest 130 (2006): 1503-10

18. Ferguson J, McEwen J, AlAjmi H, Purkins L, Colman PJ, Willavize SA "A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects." J Antimicrob Chemother 45 (2000): 503-9

19. Knoell KA, Lynch JM "Photoinduced acute exanthematous pustulosis caused by ciprofloxacin and sunlight exposure." Int J Dermatol 48 (2009): 1141-3

20. KimyaiAsadi A, Usman A, Nousari HC "Ciprofloxacin-induced bullous pemphigoid." J Am Acad Dermatol 42 (2000): 847

21. Mumford CJ, Ginsberg L "Ciprofloxacin and myasthenia gravis." BMJ 301 (1990): 818

22. Kushner JM, Peckman HJ, Snyder CR "Seizures associated with fluoroquinolones." Ann Pharmacother 35 (2001): 1194-8

23. McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991): 909-10

24. Jay GT, Fitzgerald JM "Ciprofloxacin-induced delirium." Ann Pharmacother 31 (1997): 252

25. Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993): 115-6

26. Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987): 139-41

27. Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988): 882

28. Paton JH, Reeves DS "Fluoroquinolone antibiotics: microbiology, pharmacokinetics and clinical use." Drugs 36 (1988): 193-228

29. McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991): 528-9

30. Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989): 170-1

31. Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993): 1619-21

32. Pastor P, Moitinho E, Elizalde I, Cirera I, Tolosa E "Reversible oral-facial dyskinesia in a patient receiving ciprofloxacin hydrochloride." J Neurol 243 (1996): 616-7

33. Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994): 869-72

34. Arcieri G, August R, Becker N, et al "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986): 220-5

35. Maddix DS, Stefani A "Myasthenia gravis and ciprofloxacin." Ann Pharmacother 26 (1992): 265-6

36. Cohen JS "Peripheral neuropathy associated with fluoroquinolones." Ann Pharmacother 35 (2001): 1540-7

37. Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990): 138-40

38. Whyte CA, Shivdat-Nanhoe R, Kramer P "A Case of Amoxicillin-Induced Meningitis." Clin Infect Dis 46 (2008): 642

39. Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991): 465-8

40. Arcieri G, Griffith E, Gruenwaldt G, et al "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988): 179-89

41. Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989): 558-9

42. Darwish T "Ciprofloxacin-induced seizures in a healthy patient." N Z Med J 121 (2008): 104-5

43. Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990): 595-6

44. Tattevin P, Messiaen T, Pras V, Ronco P, Biour M "Confusion and general seizures following ciprofloxacin administration." Nephrol Dialysis Transplant 13 (1998): 2712-3

45. Fleming LW, Phillips G, Stewart WK, Scott AC "Oral ciprofloxacin in the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis." J Antimicrob Chemother 25 (1990): 441-8

46. Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990): 1165-6

47. Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994): 1411

48. Tomas S, Pedro-Botet J, Auget T "Ciprofloxacin and immunocomplex-mediated disease." J Intern Med 230 (1991): 550-1

49. Granowitz EV "Photosensitivity rash in a patient being treated with ciprofloxacin." J Infect Dis 160 (1989): 910-1

50. Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995): 1600-7

51. Tierney BC, Martin SW, Franzke LH, et al. "Serious Adverse Events among Participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for Persons at Risk for Bioterrorism-Related Inhalational Anthrax." Clin Infect Dis 37 (2003): 905-11

52. Nedorost ST, Dijkstra JW, Handel DW "Drug-induced photosensitivity reaction." Arch Dermatol 125 (1989): 433-4

53. Imrie K, Gold W, Salit I, Keating A "Ciprofloxacin-induced neutropenia and erythema multiforme." Am J Hematol 43 (1993): 159-60

54. Hallgren J, Tengvall-Linder M, Persson M, Wahlgren CF "Stevens-Johnson syndrome associated with ciprofloxacin: A review of adverse cutaneous events reported in Sweden as associated with this drug." J Am Acad Dermatol 49(5 Suppl) (2003): 267-9

55. Peters B, Pinching AJ "Fatal anaphylaxis associated with ciprofloxacin in a patient with AIDS related complex." BMJ 298 (1989): 605

56. Ho DY, Song JC, Wang CC "Anaphylactoid reaction to ciprofloxacin." Ann Pharmacother 37 (2003): 1018-23

57. Win A, Evers ML, Chmel H "Stevens-johnson syndrome presumably induced by ciprofloxacin." Int J Dermatol 33 (1994): 512-4

58. Miller MS, Gaido F, Rourk MH Jr, Spock A "Anaphylactoid reactions to ciproflaxacin in cystic fibrosis patients." Pediatr Infect Dis J 10 (1991): 164-5

59. Stubbings J, Sheehan-Dare R, Walton S "Cutaneous vasculitis due to ciprofloxacin." BMJ 305 (1992): 29

60. Jongen-Lavrencic M, Schneeberger PM, van der Hoeven JG "Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus." Infection 31 (2003): 428-9

61. Maunz G, Conzett T, Zimmerli W "Cutaneous vasculitis associated with fluoroquinolones." Infection 37 (2009): 466-8

62. Kennedy CA, Goetz MB, Mathisen GE "Ciprofloxacin-induced anaphylactoid reactions in patients infected with the human immunodeficiency virus." West J Med 153 (1990): 563-4

63. Davis H, Mcgoodwin E, Reed TG "Anaphylactoid reactions reported after treatment with ciprofloxacin." Ann Intern Med 111 (1989): 1041-3

64. Lieu PK, Tok SC, Ismail NH, Chng HH "Ciproflaxin-induced cutaneous vasculitis." Allergy 52 (1997): 593-4

65. Slama TG "Serum sickness-like illness associated with ciprofloxacin." Antimicrob Agents Chemother 34 (1990): 904-5

66. Wurtz RM, Abrams D, Becker S, Jacobson MA, Mass MM, Marks SH "Anaphylactoid drug reactions to ciprofloxacin and rifampicin in HIV-infected patients." Lancet 1 (1989): 955-6

67. Tham TC, Allen G, Hayes D, et al "Possible association between toxic epidermal necrolysis and ciprofloxacin." Lancet 338 (1991): 522

68. Choe U, Rothschild BM, Laitman L "Ciprofloxacin-induced vasculitis." N Engl J Med 320 (1989): 257-8

69. Berger TG, Franklin N "Anaphylactoid reaction to ciprofloxacin in a patient infected with the human immunodeficiency virus." J Am Acad Dermatol 26 (1992): 256-7

70. Reano M, Vives R, Rodriguez J, Daroca P, Canto G, Fernandez J "Ciprofloxacin-induced vasculitis." Allergy 52 (1997): 599-600

71. Rodriguez E, Martinez JA, Torres M, Nubiiola A, Buges J "Lobular panniculitis associated with ciprofloxacin." Br Med J 300 (1990): 1468

72. Labowitz JK, Silverman WB "Cholestatic jaundice induced by ciprofloxacin." Dig Dis Sci 42 (1997): 192-4

73. Villenueuve JP, Davies C, Cote J "Suspected ciprofloxacin-induced hepatotoxicity." Ann Pharmacother 29 (1995): 257-9

74. Sherman O, Beizer JL "Possible ciprofloxacin-induced acute cholestatic jaundice." Ann Pharmacother 28 (1994): 1162-4

75. Grasmick BK, Lehr VT, Sundareson AS "Fulminant hepatic failure possibly related to ciprofloxacin." Ann Pharmacother 26 (1992): 636-9

76. Fuchs S, Simon Z, Brezis M "Fatal hepatic failure associated with ciprofloxacin." Lancet 343 (1994): 738-9

77. Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991): 638-9

78. Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989): 518-21

79. Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993): 2705-6

80. Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007): 330-5

81. Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990): 337-40

82. Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988): 170

83. Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989): 75-8

84. Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992): 248

85. Andrews PA, Robinson GT "Intravascular haemolysis and interstitial nephritis in association with ciprofloxacin." Nephron 83 (1999): 359-60

86. Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990): 987-9

87. Shih DJ, Korbet SM, Rydel JJ, Schwartz MM "Renal vasculitis associated with ciprofloxacin." Am J Kidney Dis 26 (1995): 516-9

88. Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990): 2187-9

89. Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991): 1083-4

90. Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990): 432-3

91. Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986): 408-17

92. Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990): 379-80

93. Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995): 114

94. Qian Q, Nasr SH, Akogyeram CO, Sethi S "Myoglobin-associated acute kidney injury in the setting of ciprofloxacin administration." Am J Kidney Dis 59 (2012): 462-6

95. Poon CCH, Sundaram NA "Spontaneous bilateral Achilles tendon rupture associated with ciprofloxacin." Med J Aust 166 (1997): 665

96. Mcgarvey WC, Singh D, Trevino SG "Partial achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review." Foot Ankle Int 17 (1996): 496-8

97. Alfaham M, Holt ME, Goodchild MC "Arthropathy in a patient with cystic fibrosis taking ciprofloxacin." Br Med J (Clin Res Ed) 295 (1987): 699

98. Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997): 120

99. Samuelson WM, Pleasants RA, Whitaker MS "Arthropathy secondary to ciprofloxacin in an adult cystic fibrosis patient." Ann Pharmacother 27 (1993): 302-3

100. Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410

101. Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994): 736-7

102. Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996): 516-20

103. Berger RE "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." J Urol 174 (2005): 165

104. Nair MK, Patel K, Starer PJ "Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient." Addiction 103 (2008): 2062-4

105. Owens RC Jr, Nolin TD "Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest." Clin Infect Dis 43 (2006): 1603-1611

106. Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72

107. Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72

108. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S "Fluoroquinolones and the risk of serious arrhythmia: a population-based study." Clin Infect Dis 55 (2012): 1457-65

109. Atasoy H, Erdem G, Ceyhan M, Ecevit Z, Kanra G "Hypertension asociated with ciprofloxacin use in an infant." Ann Pharmacother 29 (1995): 1049

110. Briasoulis A, Agarwal V, Pierce WJ "QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used Medications." Cardiology 120 (2011): 103-110

111. Starr JA, Ragucci KR "Thrombocytopenia associated with intravenous ciprofloxacin." Pharmacotherapy 25 (2005): 1030-4

112. Dutta TK, Badhe BA "Ciprofloxacin-induced bone marrow depression." Postgrad Med J 75 (1999): 571-3

113. Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG "Levofloxacin-induced autoimmune hemolytic anemia." Ann Pharmacother 37 (2003): 1010-3

114. Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010): e5-6

115. Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004): 295-7

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.